Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31546273 | 0.98 | PDPK1 (0.56) | PDPK1PTGS1TGFBR1PTGS2 | |
| SCHEMBL5067043 | 0.85 | KLKB1 (0.45) | PDPK1PTGS1 | |
| SCHEMBL4752045 | 0.84 | PDPK1 (0.54) | PDPK1PTGS1TGFBR1PTGS2 | |
| SCHEMBL18865866 | 0.83 | PDPK1 (0.53) | PDPK1PTGS1TGFBR1PTGS2 | |
| SCHEMBL18865526 | 0.83 | PDPK1 (0.53) | PDPK1PTGS1TGFBR1PTGS2 | |
| SCHEMBL31625278 | 0.83 | PDPK1 (0.53) | PDPK1PTGS1TGFBR1PTGS2 | |
| SCHEMBL538151 | 0.82 | PTGS2 (0.51) | PDPK1PTGS1PTGS2 | |
| SCHEMBL537395 | 0.82 | PTGS1 (0.65) | PDPK1PTGS1PTGS2 | |
| SCHEMBL24467973 | 0.81 | KLKB1 (0.54) | PDPK1PTGS1TGFBR1PTGS2 | |
| SCHEMBL7402120 | 0.81 | PTGS2 (0.65) | PDPK1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129135-A2 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025129076-A1 | PYRIDOPYRIMIDINE AND QUINAZOLINE DERIVATIVES AS USP1 INHIBITORS, COMPOSITIONS COMPRISING THEM AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-119731178-A | USP1 inhibitors and uses thereof | 福马治疗有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024233665-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-1767528-B1 | PROCESS FOR PRODUCING 5-HYDROXY-4-THIOMETHYLPYRAZOLE COMPOUND | IHARA CHEMICAL IND CO (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-1990336-B1 | PROCESS FOR PRODUCTION OF 5-ALKOXY-4-HYDROXYMETHYLPYRAZOLE COMPOUND | IHARA CHEMICAL IND CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-7812175-B2 | Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-12 | — | — | US | disclosed |
| US-7488831-B2 | Process for producing 5-hydroxy-4-thiomethylpyrazole compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-20090036688-A1 | Process for Production of 5-Alkoxy-4-Hydroxymethylpyrazole Compound | IHARA CHEMICAL INDUSTRY CO., LTD (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1990336-A1 | PROCESS FOR PRODUCTION OF 5-ALKOXY-4-HYDROXYMETHYLPYRAZOLE COMPOUND | Ihara Chemical Industry Co., Ltd. (JP) | 2008-11-12 | — | — | EP | disclosed |
| US-20070185334-A1 | Process for producing 5-hydroxy-4-thiomethylpyrazole compound | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1767528-A1 | PROCESS FOR PRODUCING 5-HYDROXY-4-THIOMETHYLPYRAZOLE COMPOUND | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | PDPK1 2458/4885PTGS1 1647/4885TGFBR1 2113/4885 |
| US-20090036688-A1 | Process for Production of 5-Alkoxy-4-Hydroxymethylpyrazole Compound | CYP4F3, ADH5, CYP3A4 | PDPK1 3549/4885PTGS1 2416/4885TGFBR1 2693/4885 |
| US-20070185334-A1 | Process for producing 5-hydroxy-4-thiomethylpyrazole compound | CYP3A5, CYP4F11, GTF3C5 | PDPK1 3135/4885PTGS1 406/4885TGFBR1 2231/4885 |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | PDPK1 3284/4885PTGS1 1075/4885TGFBR1 2692/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | PDPK1 3284/4885PTGS1 1075/4885TGFBR1 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.